The effect of rituximab treatment on FFS and OS; results of Cox regression analysis
| R-DHAP v DHAP . | Unadjusted . | Adjusted * . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| FFS | 0.51 | 0.37-0.70 | <.001 | 0.41 | 0.29-0.57 | <.001 |
| OS | 0.76 | 0.52-1.10 | .15 | 0.60 | 0.41-0.89 | .001 |
| R-DHAP v DHAP . | Unadjusted . | Adjusted * . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| FFS | 0.51 | 0.37-0.70 | <.001 | 0.41 | 0.29-0.57 | <.001 |
| OS | 0.76 | 0.52-1.10 | .15 | 0.60 | 0.41-0.89 | .001 |
Cox-regression analysis was performed to demonstrate the effect of rituximab treatment on FFS and OS without (unadjusted) and with adjustment (adjusted) for time since upfront treatment, sAAIPI, age, and WHO performance status.